In summary, based on preclinical and clinical studies, the addition of a dual GLP-1/GIP receptor agonist like CT-868 to insulin therapy for the treatment of T1D in patients with overweight or obesity could offer significant benefits in terms of improved glycemic control, reduced insulin doses, and weight loss, while also likely having a favorable safety and tolerability profile due to its intentional signaling bias
Following manufacturer guidelines ensures optimal medication stability and therapeutic effect
However, non-lactulosebased management approaches may be necessary due to nonadherence (eg, lactulose poor tolerability/adverse events/titration issues), which can precipitate HE
Research also points to a strong gut-brain connection
The proliferation of virtual pharmacies that exist largely to prescribe GLP-1s, with no other long-term patient-doctor relationship, adds to the risk that people go on these drugs without appropriate supervision and support
